Therapeutic preparation for inhalation
AssigneeAstra AB
InventorsKjell G. E. Backstrom, Carl M. O. Dahlback, Peter Edman, Ann C. B. Johansson
Life of this patent
Estimating the term…
Abstract
A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.
Claims33
A therapeutic preparation, comprising active compounds (A) insulin and (B) a substance which enhances the absorption of insulin in the lower respiratory tract, in the form of a dry powder suitable for inhalation in which at least 50% of the total mass of active compounds consists of (a) particles having a diameter of up to 10 microns or (b) agglomerates of such particles.
A therapeutic preparation comprising active compounds (A) insulin and (B) sodium caprate, which preparation is in the form of a dry powder suitable for inhalation, in which at least 50% of the total mass of active compounds (A) and (B) consists of (a) primary particles having a diameter of less than 10 microns, or (b) agglomerates of such particles.
A therapeutic preparation comprising insulin, sodium caprate and a pharmaceutically acceptable carrier, which preparation is in the form of a dry powder suitable for inhalation, of which at least 50% by mass consists of (a) particles having a diameter of less than about 10 microns, or (b) agglomerates of said particles.
A therapeutic preparation, comprising
- active compounds (A) insulin and (B) sodium caprate wherein at least 50% of the total mass of active compounds (A) and (B) consists of particles having a diameter of less than about 10 microns, and
- a pharmaceutically acceptable carrier,
- which preparation is in the form of a dry powder suitable for inhalation in which an ordered mixture is formed between the active compounds and the pharmaceutically acceptable carrier.
A single dose, breath actuated, dry powder inhaler for single usage, containing a therapeutic preparation for inhalation, which preparation comprises active compounds (A) insulin and (B) sodium caprate and is in the form of a dry powder in which at least 50% of the total mass of active compounds (A) and (B) consists of particles having a diameter of up to 10 microns.
Dependencies are inferred from the claim text.